Europe Point-of-Care Diagnostics Market is expected to reach $12.98 billion by 2030, at a CAGR of 4.1% during the forecast period 2023–2030. Point-of-care diagnostics, or bedside tests, are diagnostic tests performed on-site by healthcare professionals. These tests provide quick and accurate results without requiring samples to be sent to a laboratory. Point-of-care diagnostics products quickly determine a marker responsible for a certain disease. These tests can be used in various point-of-care settings such as physician offices, urgent care facilities, long-term care facilities, and nursing homes. Also, these devices can be categorized as handheld, transportable, and portable based on format.
The increasing prevalence of infectious and chronic diseases, rising adoption of technical advancements to enhance the quality of point-of-care diagnostics, development of CLIA-waived POC tests, and a growing number of in-house hospital laboratories opting for PoC diagnostics are the key factors driving the Europe point of care diagnostics market. Furthermore, healthcare professionals’ increasing preference for POC tests over other lab tests and growing advanced healthcare infrastructure across European countries are expected to offer significant growth opportunities in the market. However, limited reimbursement policies and cost constraints are expected to restrain the growth of this market to some extent. In addition, low awareness regarding using PoC devices is the major challenge to the market’s growth.
In efforts to deliver effective diagnostic products, key market players are focused on simplifying and automating disease diagnosis and detection steps, revolutionizing disease diagnosis processes. For instance, manufacturers have started developing automated platforms that require minimal hands-on time by trained laboratory personnel; this has driven a shift in diagnostic testing from centralized laboratories to near-patient settings, such as hospital labs, physicians’ offices, hospital outpatient departments, and home healthcare facilities. CLIA-waived tests enable testing in point-of-care settings. These tests are simple procedures with an insignificant risk of erroneous results. Such tests can be used in several settings, including pharmacy-based clinics, urgent care centers, and hospitals. Waived tests that can be performed in physician offices include streptococcus testing, HIV testing, INR (coagulation) testing for Coumadin, and pregnancy testing. CLIA-waived tests speed up diagnosis and treatment, improving patients’ clinical outcomes.
Furthermore, CLIA-waived PoC tests bring high diagnostic sensitivity and specificity to point-of-care testing. If a test is CLIA-waived, the site or facility performing the assay does not need to document personnel qualifications and training, perform quality control procedures (unless specified in the test instructions), or conduct proficiency testing or routine quality assessment related to that assay. Thus, by securing CLIA grants, vendors can help customers by reducing the documentation burden.
Click here to: Get Free Sample Pages of this Report
Healthcare Professionals Increasing Preference for PoC Tests Over Other Lab Tests Creates an Opportunity for Market Growth
Many healthcare professionals in hospitals and clinical laboratories prefer using point-of-care diagnostics to diagnose several health conditions promptly. Healthcare professionals are replacing established diagnostic methods (microscopy, pathogen culturing, biochemical testing, conventional polymerase chain reaction (PCR), enzyme-linked immunoassay (ELISA), and other time-consuming diagnostic methods) with new point-of-care diagnostic techniques that provide higher levels of efficiency and reproducibility. The advantages of point-of-care diagnostics include faster turnaround times, convenience, cost-effectiveness, improved patient outcomes, and patient satisfaction. Point-of-care diagnostic tests deliver results in minutes or hours, whereas traditional lab tests can take days to provide results. This speed can be crucial for time-sensitive medical conditions, allowing healthcare providers to make timely decisions about patient care.
Further, PoC tests are performed on-site, eliminating the need to send samples to a laboratory. This saves time and resources and can be particularly useful for patients who live in remote or rural areas. These tests are less expensive than traditional lab tests, requiring less equipment and personnel, making them a more affordable option for healthcare providers, particularly in resource-constrained settings. PoC tests help healthcare providers make faster and more accurate diagnoses, which can lead to improved patient outcomes. For example, PoC tests for infectious diseases can help healthcare providers quickly identify and treat patients, preventing the spread of diseases. Thus, the inclination toward point-of-care methods and practices among physicians drives the growth of the Europe point-of-care diagnostics market.
The Consumables Segment is Expected to Dominate the Europe Point-of-Care Diagnostics Market in 2023
Among the offerings, in 2023, the consumables segment is expected to account for the largest share of the market. Factors such as the benefits offered by point-of-care diagnostics kits, such as ease of use, portability, and accuracy. PoC diagnostic kits are pre-packaged sets of materials and reagents for performing tests. These diagnostic kits are user-friendly, with clear instructions for use, and require minimal training, making them ideal for use in settings with limited access to trained laboratory personnel, such as rural or remote areas, which are driving the growth of this segment.
The Molecular Diagnostics Platform Segment is Expected to Register the Highest CAGR During the Forecast Period
Among the platform segments, the molecular diagnostics segment is expected to account for the largest share of the market. This segment’s large share is mainly attributed to the high sensitivity and accuracy of these tests, the growing need for advanced diagnostic techniques, and the widening applications of molecular detection tests in various fields.
Based on Application, the Blood Glucose Monitoring Segment is Expected to Dominate the Europe Point-of-Care Diagnostics Market in 2023
Among the applications, in 2023, the blood glucose monitoring segment is expected to account for the largest share of the market. The large market share of this segment is mainly attributed to the increased prevalence of diabetes and the need for glucose-monitoring devices. For instance, As per data from the International Diabetes Federation’s (IDF) Diabetes Atlas, nearly 61 million adults in Europe live with Diabetes. This number is expected to reach 67 million by 2030 and 69 million by 2045.
The Blood Sample Type Segment is Expected to Register the Highest CAGR During the Forecast Period
Based on sample type, the blood sample type segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment is driven by the availability of a wide range of tests that can be conducted using blood samples, the growing prevalence of chronic diseases, and an increasing awareness among consumers about the importance of self-monitoring.
The Home Care/Self-Testing Segment is Expected to Account for the Largest Share of the Europe Point-of-Care Diagnostics Market
Among the end users, the home care/self-testing segment is expected to account for the largest share of the Europe point-of-care diagnostics market. The fast growth of the home care/self-testing segment is primarily attributed to the increasing prevalence of chronic diseases requiring long-term care and frequent monitoring, increasing home healthcare spending, growing awareness about home care, and the increasing availability of user-friendly and advanced POC diagnostic products.
Germany: Fastest Growing Market
Germany is expected to account for the largest share of the Europe point-of-care diagnostics market in 2023. The large market share of the segment is attributed to the high geriatric population coupled with the growing prevalence of infectious and chronic diseases such as ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and cancer cases, government funding and initiatives to promote cancer screenings and the presence of key players in the country.
Key Players
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in the industry over the years. The key players profiled in the Europe point-of-care diagnostics market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux S.A. (France), QuidelOrtho Corporation (U.S.), Sekisui Diagnostics, LLC. (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), and Nova Biomedical (U.S.).
Scope of the Report:
Europe Point-of-Care Diagnostics Market Assessment, by Offerings
Europe Point-of-Care Diagnostics Market Assessment, by Platform
Europe Point-of-Care Diagnostics Market Assessment, by Technique
Europe Point-of-Care Diagnostics Market Assessment, by Sample Type
Europe Point-of-Care Diagnostics Market Assessment, by End User
Europe Point-of-Care Diagnostics Market Assessment, by Country
Key questions answered in the report:
The Europe point-of-care diagnostics market study covers the market sizes & forecasts for various point-of-care diagnostics products used in the healthcare sector. The report involves the value analysis of various segments and subsegments of the point-of-care diagnostics market at the country level.
The Europe point-of-care diagnostics market is projected to reach $12.98 billion by 2030, at a CAGR of 4.1% during the forecast period.
The consumables segment is expected to account for the largest share of the market. Factors such as the benefits offered by point-of-care diagnostics kits, such as ease of use, portability, and accuracy. POC diagnostic kits are pre-packaged sets of materials and reagents for performing tests. These diagnostic kits are user-friendly, with clear instructions for use, and require minimal training, making them ideal for use in settings with limited access to trained laboratory personnel, such as rural or remote areas, which are driving the growth of this segment.
In 2023, the lateral flow assays segment is estimated to hold the major share, owing to factors such as their one-step process, long shelf life, higher portability & lower costs compared to laboratory-based tests.
The blood sample segment is projected to create more traction during the forecast period due to the availability of a wide range of tests that can be conducted using blood samples, the growing prevalence of chronic diseases, and an increasing awareness among consumers about the importance of self-monitoring.
The increasing prevalence of infectious and chronic diseases, rising adoption of technical advancements to enhance the quality of point-of-care diagnostics, development of CLIA-waived POC tests, and a growing number of in-house hospital laboratories opting for PoC diagnostics are the key factors driving the Europe point of care diagnostics market. Furthermore, healthcare professionals’ increasing preference for POC tests over other lab tests and growing advanced healthcare infrastructure across European countries are expected to offer significant growth opportunities in the market.
The key players profiled in the Europe point-of-care diagnostics market Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), bioMérieux S.A. (France), QuidelOrtho Corporation (U.S.), Sekisui Diagnostics, LLC. (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), and Nova Biomedical (U.S.).
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing & Forecasting
2.3.1. Market Size Estimation Approach
2.3.1.1 Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth forecast Approach
2.3.2. Market Share Analysis
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Infectious and Chronic Diseases
4.2.2. Rising Adoption of Technical Advancements to Enhance the Quality of POC Diagnostics
4.2.3. Development of CLIA-waived POC Tests
4.2.4. Growing Number of In-house Hospital Laboratories Opting for POC Diagnostic Technologies
4.3. Restraints
4.3.1. Limited Reimbursement Policies
4.3.2. Cost Constraints
4.4. Opportunity
4.4.1. Healthcare Professionals’ Increasing Preference for POC Tests Over Other Lab Tests
4.4.2. Growing Advanced Healthcare Infrastructure Across European Countries
4.5. Challenges
4.5.1. Lack of Awareness Regarding the Use of POC Devices
4.6. Industry and Technology Trends
4.7. Pricing Analysis
4.8. Regulatory Analysis
5. Europe Point-of-Care Diagnostics Market Assessment, by Offering
5.1. Overview
5.2. Consumables
5.3. Instruments
5.4. Software and Services
6. Europe Point-of-Care Diagnostics Market Assessment, by Platform
6.1. Overview
6.2. Lateral Flow Assays
6.3. Molecular Diagnostics
6.4. Other Platforms
7. Europe Point-of-Care Diagnostics Market Assessment, by Applications
7.1. Overview
7.2. Blood Glucose Monitoring
7.3. Infectious Disease Testing
7.3.1. Parasitic Infections Testing
7.3.2. Blood-borne Infections Testing
7.3.2.1. Hepatitis
7.3.2.2. HIV
7.3.2.3. Other Blood-borne Infections Testing
7.3.3. Respiratory Infections Testing
7.3.3.1. Influenza
7.3.3.2. Pneumonia
7.3.3.3. Tuberculosis (TB)
7.3.3.4. COVID-19 Testing
7.3.3.5. Other Respiratory Infections Testing
7.3.4. Healthcare-associated Infections (HAI) Testing
7.3.5. Gastrointestinal Infections Testing
7.3.5.1. Salmonellosis
7.3.5.2. E. Coli Infections
7.3.5.3. Other GI Infections Testing
7.3.6. Other Infectious Diseases Testing
7.4. Tumor/Cancer Markers Testing
7.5. Pregnancy And Fertility Testing
7.5.1. Pregnancy Testing
7.5.2. Fertility Testing
7.6. Cardiac Marker/Cardiac Metabolism Testing
7.7. Cholesterol/Lipid Profile Testing
7.8. Coagulation Testing
7.8.1. Prothrombin Time (PT/INR) Testing
7.8.2. Activated Clotting Time (ACT/APTT) Testing
7.8.3. Other Coagulation Testing
7.9. Hematology
7.10. Drugs of Abuse Testing
7.11. Urinalysis
7.12. Other POC Diagnostic Testing
8. Europe Point-of-Care Diagnostics Market Assessment, by Sample Type
8.1. Overview
8.2. Blood Sample
8.3. Nasopharyngeal Swab
8.4. Urine Sample
8.5. Saliva Sample
8.6. Other Sample Types
9. Europe Point-of-Care Diagnostics Market Assessment, by End User
9.1. Overview
9.2. Hospitals
9.3. Home Care/Self-testing
9.4. Physician Offices & Ambulatory Care Settings
9.5. Diagnostic Laboratories
9.6. Other End Users
10. Europe Point-of-Care Diagnostics Market Assessment, by Geography
10.1. Overview
10.2. Germany
10.3. France
10.4. U.K.
10.5. Italy
10.6. Spain
10.7. Switzerland
10.8. Austria
10.9. Netherlands
10.10. Rest of Europe
11. Competitive Analysis
11.1 Overview
11.2 Key Growth Strategies
11.3 Competitive Benchmarking
11.4 Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis, by the Key Player/Key Market Ranking, 2022
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
12.1. Abbott Laboratories
12.2. F. Hoffmann-La Roche Ltd
12.3. Siemens Healthineers AG
12.4. Danaher Corporation
12.5. Thermo Fisher Scientific Inc.
12.6. Becton, Dickinson and Company (BD)
12.7. bioMérieux S.A.
12.8. QuidelOrtho Corporation
12.9. EKF Diagnostics Holdings plc
12.10. Sekisui Diagnostics, LLC.
12.11 Trinity Biotech plc
12.12. Chembio Diagnostics, Inc.
12.13. Werfen
12.14. Nova Biomedical
12.15. Other Companies
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Europe Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 2 Europe Point-of-Care Diagnostics Consumables Market, by Country, 2021–2030 (USD Million)
Table 3 Europe Point-of-Care Diagnostics Instruments Market, by Country, 2021–2030 (USD Million)
Table 4 Europe Point-of-Care Diagnostics Market for Software and Services, by Country, 2021–2030 (USD Million)
Table 5 Europe Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 6 Europe Point-of-Care Diagnostics Market for Lateral Flow Assays, by Country, 2021–2030 (USD Million)
Table 7 Europe Point-of-Care Diagnostics Market for Molecular Diagnostics, by Country, 2021–2030 (USD Million)
Table 8 Europe Point-of-Care Diagnostics Market for Other Platforms, by Country, 2021–2030 (USD Million)
Table 9 Europe Point-of-Care Diagnostics Market, by Application, 2021–2030
Table 10 Europe Point-of-Care Diagnostics Market for Blood Glucose Monitoring, by Country, 2021–2030 (USD Million)
Table 11 Europe Point-of-Care Diagnostics Market for Infectious Diseases Testing, by Type, 2021–2030 (USD Million)
Table 12 Europe Point-of-Care Diagnostics Market for Infectious Diseases Testing, by Country, 2021–2030 (USD Million)
Table 13 Europe Point-of-Care Diagnostics Market for Parasitic Infections Testing, by Country, 2021–2030 (USD Million)
Table 14 Europe Point-of-Care Diagnostics Market for Blood-borne Infections Testing, by Type, 2021–2030 (USD Million)
Table 15 Europe Point-of-Care Diagnostics Market for Blood-borne Infections Testing, by Country, 2021–2030 (USD Million)
Table 16 Europe Point-of-Care Diagnostics Market for Hepatitis, by Country, 2021–2030 (USD Million)
Table 17 Europe Point-of-Care Diagnostics Market for HIV, by Country, 2021–2030 (USD Million)
Table 18 Europe Point-of-Care Diagnostics Market for Other Blood-borne Infections, by Country, 2021–2030 (USD Million)
Table 19 Europe Point-of-Care Diagnostics Market for Respiratory Infections Testing, by Type, 2021–2030 (USD Million)
Table 20 Europe Point-of-Care Diagnostics Market for Respiratory Infections Testing, by Country, 2021–2030 (USD Million)
Table 21 Europe Point-of-Care Diagnostics Market for Influenza, by Country, 2021–2030 (USD Million)
Table 22 Europe Point-of-Care Diagnostics Market for Pneumonia, by Country, 2021–2030 (USD Million)
Table 23 Europe Point-of-Care Diagnostics Market for Tuberculosis, by Country, 2021–2030 (USD Million)
Table 24 Europe Point-of-Care Diagnostics Market for COVID-19 Testing, by Country, 2021–2030 (USD Million)
Table 25 Europe Point-of-Care Diagnostics Market for Other Respiratory Infections Testing, by Country, 2021–2030 (USD Million)
Table 26 Europe Point-of-Care Diagnostics Market for Healthcare-associated Infection (HAI) Testing, by Country, 2021–2030 (USD Million)
Table 27 Europe Point-of-Care Diagnostics Market for Gastrointestinal Infections Testing, by Type, 2021–2030 (USD Million)
Table 28 Europe Point-of-Care Diagnostics Market for Gastrointestinal Infections Testing, by Country, 2021–2030 (USD Million)
Table 29 Europe Point-of-Care Diagnostics Market for Salmonellosis, by Country, 2021–2030 (USD Million)
Table 30 Europe Point-of-Care Diagnostics Market for E. Coli Infections, by Country, 2021–2030 (USD Million)
Table 31 Europe Point-of-Care Diagnostics Market for Other GI Infections, by Country, 2021–2030 (USD Million)
Table 32 Global Point-of-Care Diagnostics Market for Other Infectious Diseases Testing, by Country, 2021–2030 (USD Million)
Table 33 Europe Point-of-Care Diagnostics Market for Tumor/Cancer Markers Testing, by Country, 2021–2030 (USD Million)
Table 34 Europe Point-of-Care Diagnostics Market for Pregnancy and Fertility Testing, by Type, 2021–2030 (USD Million)
Table 35 Europe Point-of-Care Diagnostics Market for Pregnancy and Fertility Testing, by Country, 2021–2030 (USD Million)
Table 36 Europe Point-of-Care Diagnostics Market for Pregnancy Testing, by Country, 2021–2030 (USD Million)
Table 37 Europe Point-of-Care Diagnostics Market for Fertility Testing, by Country, 2021–2030 (USD Million)
Table 38 Europe Point-of-Care Diagnostics Market for Cardiac Marker/Cardiac Metabolism Testing, by Country, 2021–2030 (USD Million)
Table 39 Europe Point-of-Care Diagnostics Market for Cholesterol/Lipid Profile Testing, by Country, 2021–2030 (USD Million)
Table 40 Europe Point-of-Care Diagnostics Market for Coagulation Testing, by Type, 2021–2030 (USD Million)
Table 41 Europe Point-of-Care Diagnostics Market for Coagulation Testing, by Country, 2021–2030 (USD Million)
Table 42 Europe Point-of-Care Diagnostics Market for Prothrombin Time (PT/INR) Testing, by Country, 2021–2030 (USD Million)
Table 43 Europe Point-of-Care Diagnostics Market for Activated Clotting Time (ACT/APTT) Testing, by Country, 2021–2030 (USD Million)
Table 44 Europe Point-of-Care Diagnostics Market for Other Coagulation Testing, by Country, 2021–2030 (USD Million)
Table 45 Europe Point-of-Care Diagnostics Market for Hematology, by Country, 2021–2030 (USD Million)
Table 46 Europe Point-of-Care Diagnostics Market for Drugs of Abuse Testing, by Country, 2021–2030 (USD Million)
Table 47 Europe Point-of-Care Diagnostics Market for Urinalysis, by Country, 2021–2030 (USD Million)
Table 48 Europe Point-of-Care Diagnostics Market for Other PoC Testing, by Country, 2021–2030 (USD Million)
Table 49 Europe Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 50 Europe Point-of-Care Diagnostics Market for Blood Sample, by Country, 2021–2030 (USD Million)
Table 51 Europe Point-of-Care Diagnostics Market for Nasopharyngeal Swab, by Country, 2021–2030 (USD Million)
Table 52 Europe Point-of-Care Diagnostics Market for Urine Sample, by Country, 2021–2030 (USD Million)
Table 53 Europe Point-of-Care Diagnostics Market for Saliva Sample, by Country, 2021–2030 (USD Million)
Table 54 Europe Point-of-Care Diagnostics Market for Other Sample Types, by Country, 2021–2030 (USD Million)
Table 55 Europe Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 56 Europe Point-of-Care Diagnostics Market for Hospitals, by Country, 2021–2030 (USD Million)
Table 57 Europe Point-of-Care Diagnostics Market for Home Care/Self-testing, by Country, 2021–2030 (USD Million)
Table 58 Europe Point-of-Care Diagnostics Market for Physician Offices & Ambulatory Care Settings, by Country, 2021–2030 (USD Million)
Table 59 Europe Point-of-Care Diagnostics Market for Diagnostic Laboratories, by Country, 2021–2030 (USD Million)
Table 60 Europe Point-of-Care Diagnostics Market for Other End Users, by Country, 2021–2030 (USD Million)
Table 61 Europe Point-of-Care Diagnostics Market, by Country, 2021–2030 (USD Million)
Table 62 Europe: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 63 Europe: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 64 Europe: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 65 Europe: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 66 Europe: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 67 Europe: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 68 Europe: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 69 Europe: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 70 Europe: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 71 Europe: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030
Table 72 Europe: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 73 Germany: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 74 Germany: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 75 Germany: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 76 Germany: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 77 Germany: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 78 Germany: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 79 Germany: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 80 Germany: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 81 Germany: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 82 Germany: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 83 Germany: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 84 France: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 85 France: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 86 France: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 87 France: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 88 France: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 89 France: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 90 France: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 91 France: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 92 France: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 93 France: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 94 France: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 95 Recent Initiatives by the U.K. Government to Combat the COVID-19 Pandemic
Table 96 U.K.: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 97 U.K.: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 98 U.K.: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 99 U.K.: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 100 U.K.: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 101 U.K.: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 102 U.K.: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 103 U.K.: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 104 U.K.: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 105 U.K.: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 106 U.K.: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 107 Italy: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 108 Italy: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 109 Italy: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 110 Italy: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 111 Italy: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 112 Italy: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 113 Italy: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 114 Italy: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 115 Italy: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 116 Italy: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 117 Italy: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 118 Spain: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 119 Spain: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 120 Spain: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 121 Spain: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 122 Spain: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 123 Spain: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 124 Spain: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 125 Spain: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 126 Spain: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 127 Spain: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 128 Spain: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 129 Switzerland: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 130 Switzerland: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 131 Switzerland: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 132 Switzerland: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 133 Switzerland: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 134 Switzerland: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 135 Switzerland: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 136 Switzerland: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 137 Switzerland: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 138 Switzerland: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 139 Switzerland: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 140 Austria: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 141 Austria: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 142 Austria: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 143 Austria: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 144 Austria: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 145 Austria: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 146 Austria: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 147 Austria: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 148 Austria: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 149 Austria: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 150 Austria: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 151 Netherlands: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 152 Netherlands: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 153 Netherlands: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 154 Netherlands: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 155 Netherlands: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 156 Netherlands: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 157 Netherlands: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 158 Netherlands: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 159 Netherlands: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 160 Netherlands: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 161 Netherlands: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 162 Rest of Europe: Point-of-Care Diagnostics Market, by Offering, 2021–2030 (USD Million)
Table 163 Rest of Europe: Point-of-Care Diagnostics Market, by Platform, 2021–2030 (USD Million)
Table 164 Rest of Europe: Point-of-Care Diagnostics Market, by Application, 2021–2030 (USD Million)
Table 165 Rest of Europe: Infectious Diseases Testing Market, by Type, 2021–2030 (USD Million)
Table 166 Rest of Europe: Respiratory Infections Market, by Type, 2021–2030 (USD Million)
Table 167 Rest of Europe: Gastrointestinal Infections Market, by Type, 2021–2030 (USD Million)
Table 168 Rest of Europe: Blood-Borne Infections Market, by Type, 2021–2030 (USD Million)
Table 169 Rest of Europe: Coagulation Testing Market, by Type, 2021–2030 (USD Million)
Table 170 Rest of Europe: Pregnancy and Fertility Testing Market, by Type, 2021–2030 (USD Million)
Table 171 Rest of Europe: Point-of-Care Diagnostics Market, by Sample Type, 2021–2030 (USD Million)
Table 172 Rest of Europe: Point-of-Care Diagnostics Market, by End User, 2021–2030 (USD Million)
Table 173 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Size Estimation
Figure 7 Europe Point-of-Care Diagnostics Market, by Offering, 2023—2030 (USD Million)
Figure 8 Europe Point-of-Care Diagnostics Market, by Platform, 2023—2030 (USD Million)
Figure 9 Europe Point-of-Care Diagnostics Market, by Application, 2023—2030 (USD Million)
Figure 10 Europe Point-of-Care Diagnostics Market, by Sample Type, 2023—2030 (USD Million)
Figure 11 Europe Point-of-Care Diagnostics Market, by End User, 2023—2030 (USD Million)
Figure 12 Europe Point-of-Care Diagnostics Market, by Country, 2023—2030 (USD Million)
Figure 13 Impact Analysis: Europe Point-of-Care Diagnostics Market
Figure 14 Market Dynamics: Europe Point-of-Care Diagnostics Market
Figure 15 Europe Point-of-Care Diagnostics Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 16 Europe Point-of-Care Diagnostics Market, by Platform, 2023 Vs. 2030 (USD Million)
Figure 17 Europe Point-of-Care Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 18 Europe Point-of-Care Diagnostics Market, by Sample Type, 2023 Vs. 2030 (USD Million)
Figure 19 Europe Point-of-Care Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 20 Europe Point-of-Care Diagnostics Market, by Country, 2023 Vs. 2030 (USD Million)
Figure 21 Europe Point-of-Care Diagnostics Market, by Offering, 2023 Vs. 2030 (USD Million)
Figure 22 Europe Point-of-Care Diagnostics Market, by Platform, 2023 Vs. 2030 (USD Million)
Figure 23 Europe Point-of-Care Diagnostics Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 24 Europe Point-of-Care Diagnostics Market, by Sample Type, 2023 Vs. 2030 (USD Million)
Figure 25 Europe Point-of-Care Diagnostics Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 26 Europe Point-of-Care Diagnostics Market, by Country, 2023 Vs. 2030 (USD Million)
Figure 27 Europe Point-of-Care Diagnostics Market Snapshot
Figure 28 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 29 Europe Point-of-Care Diagnostics Market: Vendor Dashboard
Figure 30 Europe Point-of-Care Diagnostics Market: Competitive Benchmarking, by Type
Figure 31 Abbott laboratories: Financial Snapshot, 2022
Figure 32 F. Hoffmann-La Roche Ltd: Financial Snapshot, 2022
Figure 33 Siemens Healthineers AG: Financial Snapshot, 2022
Figure 34 Danaher Corporation: Financial Snapshot, 2022
Figure 35 Thermo Fisher Scientific Inc.: Financial Snapshot 2022
Figure 36 Becton, Dickinson and Company: Financial Snapshot, 2022
Figure 37 bioMérieux S.A.: Financial Snapshot, 2022
Figure 38 QuidelOrtho Corporation: Financial Snapshot, 2022
Figure 39 EKF Diagnostics Holdings plc: Financial Snapshot, 2022
Figure 40 Sekisui Chemical Co., Ltd.: Financial Snapshot, 2022
Figure 41 Trinity Biotech plc: Financial Snapshot, 2022
Figure 42 Chembio Diagnostics: Financial Snapshot, 2022
Figure 43 Werfen: Financial Snapshot, 2022
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2024
Published Date: Jan-2024
Published Date: Dec-2023
Published Date: Nov-2023
